Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab self-injection device study in moderate to severe chronic plaque psoriasis
jRCT2080224634Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of bimekizumab in psoriasis (2 arms), sponsored by UCB. Primary endpoints: Safety and tolerability of self-injection device use and Adverse device effects. Started Apr 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on jRCT2080224634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224634.